Alpine Immune Sciences Valuation
| ALPNDelisted Stock | USD 12.37 0.23 1.83% |
At this time, the firm appears to be overvalued. Alpine Immune Sciences shows a prevailing Real Value of $9.38 per share. The current price of the firm is $12.37. Our model approximates the value of Alpine Immune Sciences from analyzing the firm fundamentals such as Current Valuation of 4.16 B, profit margin of (0.65) %, and Return On Equity of -0.15 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Alpine Immune's price fluctuation is very steady at this time. Calculation of the real value of Alpine Immune Sciences is based on 3 months time horizon. Increasing Alpine Immune's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Alpine Immune is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Alpine Stock. However, Alpine Immune's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.37 | Real 9.38 | Hype 12.37 | Naive 13.24 |
The intrinsic value of Alpine Immune's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Alpine Immune's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Alpine Immune Sciences helps investors to forecast how Alpine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Alpine Immune more accurately as focusing exclusively on Alpine Immune's fundamentals will not take into account other important factors: Alpine Immune Total Value Analysis
Alpine Immune Sciences is presently projected to have valuation of 4.16 B with market capitalization of 4.46 B, debt of 9.91 M, and cash on hands of 167.86 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Alpine Immune fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.16 B | 4.46 B | 9.91 M | 167.86 M |
Alpine Immune Investor Information
About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.64. Alpine Immune Sciences last dividend was issued on the 25th of July 2017. The entity had 1:4 split on the 25th of July 2017. Based on the measurements of operating efficiency obtained from Alpine Immune's historical financial statements, Alpine Immune Sciences is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Alpine Immune Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Alpine Immune has an asset utilization ratio of 15.42 percent. This suggests that the Company is making $0.15 for each dollar of assets. An increasing asset utilization means that Alpine Immune Sciences is more efficient with each dollar of assets it utilizes for everyday operations.Alpine Immune Ownership Allocation
Alpine Immune holds a total of 68.6 Million outstanding shares. The majority of Alpine Immune Sciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alpine Immune Sciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alpine Immune. Please pay attention to any change in the institutional holdings of Alpine Immune Sciences as this could imply that something significant has changed or is about to change at the company. Also note that nearly two million seven hundred eighty-five thousand fifty-nine invesors are currently shorting Alpine Immune expressing very little confidence in its future performance.Alpine Immune Profitability Analysis
The company reported the previous year's revenue of 58.88 M. Net Loss for the year was (32.18 M) with loss before overhead, payroll, taxes, and interest of (40.18 M).About Alpine Immune Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Alpine Immune Sciences. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Alpine Immune Sciences based exclusively on its fundamental and basic technical indicators. By analyzing Alpine Immune's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Alpine Immune's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Alpine Immune. We calculate exposure to Alpine Immune's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Alpine Immune's related companies.Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmuneinflammatory disorders, and other diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington. Alpine Immune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 85 people.
Alpine Immune Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 50 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |